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Abstract
Between 40%" and 60% of Americans use complementary and alternative medicine to manage medical conditions, prevent disease,
and promote health and well-being. Omega-3 polyunsaturated fatty acids (ro-3 PUFAs) have been used to treat joint pain associated
with several inflammatory conditions. We conducted a meta-analysis of l7 randomized, controlled trials assessing the pain relieving
effects of ro-3 PUFAs in patients with rheumatoid arthritis or joint pain secondary to inflammatory bowel disease and dysmenor-
rhea. Meta-analysis was conducted with Cochrane Review Manager 4.2.8. for six separate outcomes using standardized mean dif-
ferences (SMDs) as a measure of effect size: (1) patient assessed pain, (2) physician assessed pain, (3) duration of morning stiffuess,
(4) number of painful and/or tender joints, (5) Ritchie articular index, and (6) nonselective nonsteroidal anti-inflammatory drug
consumption. Supplementation with ro-3 PUFAs for 3-4 months reduces patient reported joint pain intensity (SMD: 
-0.26;95%
CI: 
-0.49 to -0.03, p : 0.03), minutes of morning stiffness (SMD: -0.43;95% Cl: -0.12 to -0.15, p : 0.003), number of painful
and/or tender joints (SMD: 
-0.29;95% CI: -0.48 to -0.10,p:0.003), and NSAID consumption (SMD: -0.40;95%Cl: -0.72to
- 
0.08, p : 0.01). Significant effects were not detected for physician assessed pain (SMD: 
-0.14;95% CI: -0.49 to 0.22, p: 0.45) or
Ritchie articular index (SMD: 0.15; 95% CI: 
- 
0.19 to 0.49, p :0.40) at 3-4 months. The results suggest that o-3 PUFAs are an
attractive adiunctive treatment for ioint pain associated with rheumatoid arthritis. inflammatorv bowel disease. and dvsmenorrhea.
Keywords: Omega-3 polyunsaturated latty acids; EPA; DHA; Fish oil; Inflammation; Joint pain; Rheumatoid arthritis; Inflammatory bowel disease;
Dysmenorrhea; Meta-analysis; RCT
1. Introduction
Between 40oh and 60% of Americans use complemen-
tary and alternative medicine to manage medical
conditions, prevent disease, and promote health and
well-being (Astin, 1998; Barnes et a1.,2004). Not surpris-
ingly,33oh of those who use complementary medicine cite
pain as the primary reason (Barnes et a1.,2004). Dietary
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constituents and supplements used as potential therapeu-
tic agents for the treatment of pain include dietary soy,
omega-3 polyunsaturated fatty acids (rrr-3 PUFAs),
sucrose, and anthocyanins found in tart cherries and
other fruits and vegetables with highly colored pigments
(Tall and Raja, 2004). With one exception, there is
little in the way of empirical evidence to support the safe
and effective use of dietary supplements for managing
pain. The exception is the o-3 PUFAs; controlled
trials demonstrate their efficacy in reducing joint pain
associated with inflammatory conditions, including rheu-
matoid arthritis (RA), inflammatory bowel disease, and
dvsmenorrhea.
Concern over gastrointestinal bleeding and myocar-
dial infarction associated with nonselective nonsteroidal
anti-inflammatory drugs (NSAIDs) (Langford, 2006)
and selective cyclooxygenase-2 (COX-2) inhibitors
(Andersohn et al., 2006) has prompted the search for
other treatments for chronic inflammatory pain. Dietary
supplementation with long.shrir ro-3 PUFAs, eicosa-
pentaenoic acid (EPA) (20:5cl-3), and docosahexaenoic
acid (DHA) (22:6a-3), may be an effective adjunct to
NSAID therapy (Albert et al., 2005; Calder, 2006).
The typical North American diet is very low in EPA
and DHA (Maclean et a1.,2004) and conversion is lim-
ited from dietary cdinolenic acid, found in vegetable
oils, to EPA and DHA (James et al., 2003).
Fish oil is a rich source of long-chain rrl-3 PUFAs,
typically containing 18% EPA and l2o/o DHA derived
from marine fish (Cleland eI a1.,2006).In humans, sup-
plementation with fish oil, or EPA/DHA capsules,
increases the incorporation of ay3 PUFAs into phos-
pholipids (James et a1.,2003), conferring anti-inflamma-
tory effects (Stamp et al., 2005; Calder, 2006). Early
studies reviewed by Stamp et al. (2005) and Calder
(2006) attributed these anti-inflammatory effects to
competition with arachidonic acid for production of
inflammatory eicosanoids. More recent investigations
show that EPA and DHA produce novel anti-inflamma-
tory lipids (i.e., resolvins and protectins) which appear,
in a transgenic mouse model, to have anti-inflammatory
effects (Arita et al., 2005; Lukiw et al., 2005; Hudert
et a1.,2006). Transgenic mice engineered to overexpress
fat-L, an r.rr-3 desaturase from roundworms, overpro-
duce al-3 PUFAs, resolvins and protectins. These mice
are protected from dextran sulphate-induced colitis, a
standard model of inflammation, but no change in the
levels of crr-6 PUFA-derived prostaglandin E2 (PGE2)
or leukotriene Ba (LTBa) was observed, indicating com-
petition between cl-3 PUFAs and arachidonic acid is
not important in this model (Hudert et al., 2006).
Through these, and possibly other mechanisms, EPA
and DHA inhibit activation of the transcription factor
nuclear factor rcB (NF-rB), and the release of the cyto-
kines interleukin-l beta (IL-18) and tumor necrosis
factor a (TNF-u), central regulators of inflammation
(Fig. 1) (Novak et al., 2003; Zhao et al., 2004; Chen
et al., 2405; De Caterina and Massaro, 2005; Stamp
et al., 2005; Calder, 2006; Hudert et al., 2006).
The objective of the present review is to conduct a
meta-analysis examining the pain relieving effects of
EPA/DHA in patients with RA or joint pain secondary
to inflammatory bowel disease or dysmenorrhea.
2. Methods
We followed the Quality of Reporting of Meta-analyses(QUORUM) guidelines for reporting meta-analyses of ran-
domized controlled trials (Moher et al., 1999).
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Fig. 1. Metabolism of inflammatory mediators from o6 PUFAs and
sites of inhibition by ro-3 PUFAs.
2.1. Identification of trials and inclusion criteria
The following databases were searched for entries up to
November 2006: MEDLINE, EMBASE, CINAHL (Cumula-
tive Index to Nursing & Allied Health Literature), Ovid
Healthstar and AMED (Allied and Complementary Medi-
cine). The following key words were used in the search strate-
gy: ((omega-3 or n-3 or "fish oil" or eicosapentaenoic or epa or
docosahexaenoic or dha) and ("rhetmatoid arthritis'o or "in-
flammatory bowel disease" or IBD or dysmenorrhea)). The
search was limited to English language publications and ran-
domized clinical trials. References from relevant articles were
checked for further studies.
2.2. Outcomes of interest and rationale for pooling studies
An assessment of pain was operationalized as any direct
measure or index of joint pain, joint tenderness, or joint stiff-
ness. Direct measures and indices of inflamed tissue (e.g., swol-
len joint counts) were not considered assessments of pain fioint
swelling and tenderness are not significantly correlated (Prevoo
et al., 1993)). Six different pain outcomes were identified: (l)
patient assessed pain (visual analog scale (VAS) or categorical
scale), (2) physician assessed pain (VAS or categorical scale),
(3) duration of morning stiffness (minutes or hours), (4) num-
ber of painful and/or tender joints, (5) Ritchie articular index,
a tool for assessing joint tenderness elicited from the applica-
tion of pressure over the joint margin of articular joints (Ritch-
ie et al., 1968), and (6) NSAID consumption.
All studies included in the final meta-analysis employed a
randomized design, and compared patients receiving or-3
PUFAs relative to an inert substance. Studies manipulating
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analgesic consumption during the treatment period were
excluded. Pain outcomes were considered separately, and not
pooled, so as to limit clinical heterogeneity.
2.3. Data extraction and assessment of quitity and ualidity
A data extraction process was performed on the articles
that met inclusion criteria. The following items were collected:
publication details, duration of study, patient population, sam-
ple size, dosage of ro-3 PUFA supplements, total dosage of ro-3
PUFA supplements, type of placebo, and type of NSAID
administered.
Methodological quality was measured independently by
two reviewers (RJG and JK) using the Jadad quality index
scale (Jadad et al., 1996). The scale uses a six point (0-5) rating
system (in which lower quality articles receive lower scores) to
assess the likelihood of bias in pain research reports based on
descriptions of randomization, blinding, and withdrawals.
Validity was scored independently by the same two reviewers
using the 0-16 point Oxford Pain Validity Scale (Smith
et al., 2000). Articles with lower validity receive lower scores
on the Oxford Pain Validity Scale.
The two reviewers were blinded to the authors, institutions,
addresses, acknowledgements, and publication details when
rating the quality and validity of each article. The quality
and validity scores for articles included and excluded from
analysis were compared using an independent samples t-test.
2.4. Statistical analysis
Meta-analysis was conducted with Cochrane Review Man-
ager 4.2.8. (http://www.cc-ims.net/RevMan) for the six out-
come measures using standardized meau differences (SMDs)
as a measure of effect size. In order to include as many trials
in the meta-analysis as possible, even when not all information
was reported, means and standard deviations were estimated
based on the median, range, and sample size (Hozo et al.,
2005). Estimation was performed for three studies (Cleland
et a1., 1988; Tulleken et al., 1990; Nielsen et al., 1992).
Only the most conseryative estimate of effect size was used
when an outcome measure was reported at more than one time
interval within a specified period (e.g., 9 and 12 months), or
when two different measures of the same outcome measure
were reported (e.g., patient assessed pain on a l0cm VAS
and a categorical scale). We calculated SMD instead of weight-
ed mean differences (WMDs) since several pain outcomes (e.g.,
patient assessed pain) were assessed on different scales across
the studies. Statistical heterogeneity was tested by Q test (X2)
and reported with the 12 statistic. Higher values of 12 indicate
higher heterogeneity. All meta-analyses were carried out with
the random effects model.
A primary analysis was conducted for studies administering
ro-3 PUFA supplementation for 3-4 months. Separate analyses
were also conducted for studies administering supplementation
for less than two months, and longer than 5 months. These
three time intervals were based on previous reports suggesting
that the therapeutic effects of or-3 PUFAs are usually manifest
after approximately 3 months (Stamp et al., 2005). We hypoth-
esized that patients taking ro-3 PUFA supplementation for
2 months or less would not benefit significantly.
Articles were categorized based on dose of ro-3 PUFA
intake (high-dose intake, low-dose intake), and the dietary
supplement/placebo given to the control group (olive oil,
non-olive oil). A daily r*3 PUFA intake of 2.7 gwas used to
distinguish high-dose and low-dose o3 PUFA intake based
on previous reports in RA which recommend a dose of 2.7-
4.0 g per day of EPA and DHA combined (Stamp et al.,
2005). For studies reporting outcomes at 3-4 months, sub-
group analyses were performed based on dose of ro-3 PUFAs
and type ofplacebo.
3. Results
3.1. Triols and patients
Our search strategy (Fig. 2) identified 24 articles (and
one abstract (Darlington and Ramsey, 1987)) assessing
the effects of dietary rll-3 PUFA supplementation onjoint pain outcomes (Kremer et al., 1985; Kremer
et al.,19871' Belch et al., 1988; Cleland et al., 1988; Mag-
aro et al., 1988; Tulleken et al., 1988; Kremer et al.,
1990; Tulleken et al., 1990; van der Tempel et al.,
1990; Kjeldsen-Kragh et al., 1992; Nielsen et al., 1992;
Skoldstam et al., 1992; Lau et al., 1993; Geusens et al.,
1994; Kremer et al., 1995; Nordstrom et a1., 1995; Han-
sen et al., 1996; Volker et al., 2000; Adam et al., 2003;
Sampalis et al., 2003; Bjorkkjaer et al., 2004; Remans
et a1.,2004; Sundrarjun et al., 2004; Berbert et al.,
2005). Two trials were excluded from the meta-analysis
due to an experimental design involving concomitant
supplementation of o-3 PUFAs with NSAIDs followed
Fig. 2. Modified flow diagram of search strategy based on the
QUORUM guidelines, RCTs: randomized controlled trials.
60 Potentially relevant articles
identified and screened for retrieval
24 paper copies were retrieved for
more detailed evaluation
3 studies excluded:
- 2 due to experimental design
involving concomitant
supplementation of omega-3 PUFA
with NSAIDs
- I due to non-randomized
experimental design
2l potentially appropriate RCTS for
inclusion in the meta-analysis
4 RCTs excluded due to
insufficient data for meta-analysis
by a stepwise reduction in NSAID consumption over the
duration of the study (Kjeldsen-Kragh et al., 1992; Kre-
mer et al., 1995). A third trial was excluded due to a
non-randomized design (Kremer et al., 1987). Four pla-
cebo-controlled studies were not included because they
did not report suffcient data (Belch et al., 1988; Tulle-
ken et al., 1988; Hansen et a1.,1996; Volker et al., 2000). --
Seventeen studies reporting sufficient data for meta-
analysis (Table 1), with a total of 823 patients, were
included in the final analysis. Six studies reported at
least one pain outcome at two months or less, 16 report-
ed at least one pain outcome at 34 months, and six
studies reported at least one pain outcome at 5 months
or longer. We did not include the results for morning
stiftress and number of tender joints from one study
(Bjorkkjaer et al., 2004) due to significant between
group differences at baseline.
3.2. Outcome measlres
3.2.1. Main analysis
A meta-analysis of 16 studies at34 months (Kremer
et a1., 1985; Cleland et a1., 1988; Kremer et al., 1990;
Tulleken et al., 1990; van der Tempel et al., 1990; Niel-
sen et al., 1992; Skoldstam et al.,1992; Lau et al.,1993;
Geusens et al., 1994; Nordstrom et al., 1995; Adam
et al., 2003; Sampalis et al., 2003; Bjorkkjaer et al.,
2004; Remans et al., 2004; Sundrarjun et a1.,2004; Ber-
bert et al., 2005) showed significant effects for four of six
pain outcomes: patient assessed pain, morning stiffness,
number of painful and/or tender joints, and NSAID
consumption (Fig. 3). In contrast, significant effects were
not detected for physician assessed pain and Ritchie
articular index.
Patient assessed pain was reported in 19 studies at
3-4 months. Thirteen studies provided sufficient data
for meta-analysis. Of these 13 studies, 2 found a sig-
nificant improvement relative to placebo, seven noted
an improvement in patients receiving ro-3 PUFAs
that did not reach significance, and four reported
no difference between o>3 PUFAs and placebo. One
study (Cleland et al., 1988) reporting a non-signifi-
cant difierence in patient assessed pain between ro-3
PUFAs and placebo groups reported a significant
improvement in patient assessed pain in the olive
oil group. Overall, patients receiving or-3 PUFAs
fared better than placebo for patient assessed pain
(SMD: 
- 
0.26; 95% confidence interval [CI]: 
-0.a9to 
- 
0.03, p : 0.03). Of the six studies not reporting
sufficient data for meta-analysis (Kremer et a1., 1985;
Belch et al., 1988; Lau et al., 1993; Hansen et a1.,
1996; Volker eI al., 2000; Adam et a1., 2003), three
found a significant improvement relative to placebo,
one found an improvement that favoured ro-3 PUFAs
but did not reach significance, and two found no dif-
ference between groups.
Morning stiffness was reported in 16 studies at 3-
4 months. Eight studies provided sufficient data for
meta-analysis. Of these eight studies, two found a signif-
icant improvement relative to placebo, one found a sig-
nificant improvement in the o-3 PUFAs group relative
to baseline, four reported an improvement in patients
receiving co-3 PUFAs that did not reach significance,
and one did not find a difference. Overall, patients
receiving rrr3 PUFAs fared better than placebo for
morning stiffness (SMD: 
-0.43; 95% Cl: - 0.72 to
-0.15, p :0.003). Among the eight studies not report-
ing sufficient data for meta-analysis (Belch et al., 1988;
Tulleken et al., 1988; Skoldstam et al., 1992; Lau
et al., 1993; Geusens et al., 1994; Hansen et al., 1996;
Volker et al., 2000; Adam et a1., 2003), three reported
a signifi.cant improvement relative to placebo, and fi.ve
found no difference between groups.
Number of painful atdlor tender joints was reported
in 11 studies at34 months, 10 of which provided suffi-
cient data for meta-analysis. Of these l0 studies, one
found a significant improvement relative to placebo,
two found a significant improvement in the trl.3 PUFA
group relative to baseline (one of which also noted a sig-
nificant, but less pronounced, improvement in the place-
bo group), five noted an improvement in patients
receiving rrl-3 PUFAs that did not reach significance,
and two did not find any between gtoup differences.
Overall, patients receiving ar3 PUFAs fared better than
placebo for number of painful and/or tender joints
(SMD: 
-0.29; 95% CI: -0.48 to - 0.10, p:0.003).
One study reporting insufficient data for meta-analysis
(Volker et al., 2000) found a significant improvement
relative to placebo.
NSAID consumption was reported in six studies at 3-
4 months, three of which provided sufficient data for
meta-analysis. Of these three studies, two found a signif-
icant decrease in NSAID use relative to placebo and one
did not find any between group differences. Overall,
patients receiving o-3 PUFAs fared better than placebo
for NSAID consumption (SMD: 
-0.40; 95% CI: -0.12to 
- 
0.08, p : 0.01). Among the three studies reporting
insufficient data for meta-analysis (Belch et al., 1988;
Kremer et a1., 1990; Hansen et a1.,7996), two found a
significant improvement relative to placebo, and one
did not find any between group differences.
Of the six studies reporting outcomes at 5 months or
longer (Fig. 4), significant improvements were detected
for two of the six pain outcomes: physician assessed pain
(SMD: 
-0.50; 95% CI: - 0.98 to -0.01, p:0.05) and
number of painful and/or tender joints (SMD: 
-0.51;
95% Cl: 
-1.00 to -0.02, p:0.04).It is important to
note that effect sizes among studies of ctl-3 PUFA sup-
plementation for 5 months or longer were generally larg-
er than effect sizes at 34 months. However, due to the
limited number of studies available and corresponding
lack of statistical power, only two outcome measures
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Roview: Omega"S polyunsturat€d fary acids for pain
Comparion: 02 Omega-3 polyuNaturat€d latty acids versus placabo lor joint pain: supplomenlalion lor 3q months
Outcome: 0lPatisnl'sA$ossmenlofPain
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Fig. 3. Analysis of data used in overall result assessment from studies providing 3-4 month supplementation of o-3 PUFAs. Conducted using
Cocbrane Review Managet 4.2.8. software. SD, standard deviation; SMD, standardized mean difference; CI, confidence interval.
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showed significant improvements. Improvements in
morning stiffness and NSAID consumption were noted,
though this result did not reach significance (SMD:
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were not found for patient assessed pain and Ritchie
articular index. Of the six studies reporting outcomes
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at two months or less (Fig. 5), significant effects were not
found in any pain outcome measures. Improvement in
Ritchie articular index was observed at two months or
less (SMD: 
- 
I.22; 95oh CI:. 
-2.50 to 0.06, p:0.06);
however, this result is based on a small sample size(n:6) from only one study.
3.2.2. Subgroup analyses
3. 2. 2. 1. High-do se uersus low-dose supplementation. Slub-
group analyses were conducted based on the dose of rrl-3
PUFAs as well as type of placebo (olive oil or non-olive
oil). Studies that provided high-dose rrr-3 PUFAs (i.e.,
>2.7 g/day of EPA and DHA) showed greater improve-
ments in morning stiffness (SMD: 
-0.50; 95% CI: -0.81
to 
-0.19,p:0.001), and number of painful and/or ten-
der joints (SMD: 
-0.46; 95ok CI: -0.76 to -0.17,p:0.0A2) compared to low-dose rrr-3 PUFAs (SMD:
-0.30; 9 5% CI: - 1,07 to 0.48, p : 0.46 for morning stiff-
ness, SMD: 
-0.12; 95% CI: -0.40 to 0.16, p: 0.38 for
number of painful andlor tender joints). Although
patient assessed pain was significant for high-dose, but
not low-dose rrl-3 PUFAs, the effect sizes were compara-
ble (SMD: 
-0.22;95% CI: -0.44 to 0.00, p:0.05 for
high-dose, and SMD: 
-0.32; 95o/o CI: -1.04 to 0.39,
p :0.37 for low-dose) raising the possibility of insuffi-
cient power for the low-dose effect size.
3.2.2.2. Oliue oil uersus non-oliue oil placebo. Studies
employing a non-olive oil placebo showed greater
improvements for patient assessed pain (SMD: 
-0.43;
95% CI: 
-0.74 to -0.12, p:0.007) and morning stiff-
ness (SMD: 
-0.54; 95% CI: - 0.87 to -0.21,p:0.001) relative to studies employing an olive oil pla-
cebo (SMD: 
-0.07; 95% Cl: -0.39 to 0.24, p: 0.65 for
patient assessed pain, and SMD: 
-0.12;95o/o Cl: - 0.63
to 0.40, p:0.66 for morning stiffness). There was little
difference in painful and/or tender joint count between
olive oil-controlled studies (SMD: 
-0.39; 95% CI:
-0.76 to - 0.02, p :0.04) and non-olive oil-controlled
studies (SMD: 0.25;95% CI: 
-0.52 to 0.03,p:0.08), as
both showed favourable results. One study was excluded
from this analysis since the type of placebo administered
was not reported (Sundrarjun et a1.,2004).
3.3. Methodological quality and ualidity
The Jadad et al. (1996) quality index scores ofthe 17
articles ranged from one to five with a mean * SD of
3.1 + 1.1. Twelve of these trials received three or more
points, and five trials received two or fewer points.
Among the seven studies excluded from analysis, scores
ranged from one to four with a mean * SD of 3.0 + 1.2.
Five of these trials received three or more points, and
two received two or fewer points. The mean quality
score of the included versus excluded articles did not dif-
fer significantly (t(22):0.24, p : 0.81).
We sought to determine how exclusion of poor qual-
ity trials scoring two points or less on the Jadad et al.
(1996) scale would affect the results. Exclusion of these
trials had no material effect on the outcomes of the main
analysis (p values that were (non) significant with all tri-
als included remained so when poor quality trials were
excluded).
The Oxford Pain Validity Scale scores (Smith et al.,
2000) of the 17 articles included in analysis ranged
from five to 14 with a mean * SD of 10.8 + 2.9. Among
the seven studies excluded from analysis, scores ranged
from five to 12. with a mean * SD of 9.412.3. The
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Fig. 4. Analysis of data used in overall result assessment from studies providing supplementation of trl-3 PUFA for longer than 5 months. Conducted
using Cochrane Review Manager 4.2.8. software. SD, standard deviation; SMD, standardized mean difrerence; CI, confidence interval.
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Fig. 5. Analysis of data used in overall result assessment from studies providing less than two months supplementation of o-3 PUFAs. Conducted
using Cochrane Review Managet 4.2.8. software. SD, standard deviation; SMD, standardized mean difierence; CI, confidence interval.
mean validity score of the included versus excluded
articles did not differ significantly (t(221:1.99,
p :0.29).
4. Discussion
The results of the present meta-analysis support the
hypothesis that o3 PUFA supplementation improves
pain outcomes after three months, particularly with
respect to patient assessed pain, duration of morning
stiffness, number of painful and/or tender joints, and
NSAID consumption.
Two previous meta-analyses of ot-3 PUFA supple-
mentation for RA have been published. The first was
conducted more than 10 years ago (Fortin et al., 1995)
and found a modest effect of fish oil supplementation
on joint tenderness and morning stiffness after three
months. The second meta-analysis (Maclean et al.,
2004) did not detect any effect on patient assessed pain.
In contrast to the present meta-analysis which focused
on six pain-related outcomes, Maclean et al, (2004)
focused on immune mediated diseases, bone metabo-
lism, and gastrointestinal/ renal diseases. Our results dif-
fer from the previous meta-analyses in showing a
stronger effect than that reported by Fortin et al.
(1995) and a beneficial effect compared to the lack of
effect for patient assessed pain by Maclean et al.
(2004). Reasons for the discrepancy between the results
of the present meta-analysis and the earlier ones include
the fact that Fortin et al. (1995) did not include mea-
sures of patient assessed pain, physician assessed pain,
Ritchie articular index, or NSAID consumption, and
Maclean et al. (2004) only addressed patient assessed
pain and NSAID consumption. Furthermore, we
reported on eight additional trials that were either not
included by Fortin et al. (1995) and Maclean et al.
(2004) or were published subsequently. We also included
one study measuring joint pain in patients with dysmen-
orrhea (Sampalis et a1.,2003) and one measuring rheu-
matic joint pain in patients with inflammatory bowel
disease (Bjorkkjaer et al., 2004). Finally, we excluded
one non-randomized trial (Kremer et al., 1987) that For-
tin et al. (1995) included.
Notwithstanding the positive outcome of the present
meta-analysis, a number of factors may have reduced
the apparent efficacy of o>3 PUFAs in the studies ana-
lyzed. (l) The use of a variety of doses and treatment
periods in different studies limited the effect size detect-
ed. With the exception of two studies (Kremer et al.,
1990; Adam et a1.,2003), a dosage of rrr-3 PUFAs rel-
ative to patient body weight was not provided. (2)
Consideration of treatment time showed that a mini-
mum of three months was required for a therapeutic
effect, but there were only six studies available for
the 6-month analysis, thus decreasing the power for
this analysis. (3) It was previously suggested that a
dose of 2.7 glday of EPA and DHA is required to
achieve anti-inflammatory effects (Stamp et al., 2005).
One study indeed found that high-dose ro-3 PUFAs
were more effective than a low-dose in reducing pain
in RA (Geusens et al., 1994). In our analysis, 11 of
the 16 studies aL 34 months used a dose of EPA/
DHA above 2.7 g ro-3 PUFAs per day. Significant
improvements were noted in patient assessed pain
and morning stiffness among studies providing high-
dose but not low-dose rrl-3 PUFA supplementation.
(4) The use of additional analgesics and supplements
likely further obscures the benefits of EPA/DHA sup-
plementation but many studies did not provide these
data. (5) Long-chain ro-3 PUFAs compete with other
fatty acids for incorporation into phospholipids.
Reducing the intake of ro-6 fatty acids (e.g., linoleic
acid), which are metabolized to arachidonic acid and
inflammatory eicosanoids, would be expected to
increase the effectiveness of ar-3 PUFA supplements
(Stamp et al., 2005). Indeed, a study of RA patients
demonstrated greater efficacy of EPA/DHA when ro-6
PUFA consumption was decreased (Adam et al.,
2003). Linoleic acid intake was not controlled in most
of the studies analyzed. (6) Olive oil was used as the
placebo in the control group in some of the studies
(Cleland et al., 1988; Kremer et al., 1990; Skoldstam
et al., 1992; Geusens et al., 1994), but olive oil itself
may have anti-inflammatory properties, thereby lessen-
ing the relative effects of EPA/DHA when compared
with (olive oil) placebo. The main constituent of olive
oil, oleic acid, may compete with arachidonic acid for
incorporation into phospholipids. Olive oil also con-
tains phenols, such as tyrosol and B-sitosterol, which
have anti-inflammatory actions (Moreno et al., 2001).
(7) Finally, in most of the studies, it was not noted
whether precautions were taken to prevent oxidation
of EPA/DHA.
In order to maximize the therapeutic effects and
improve the quality and validity of future trials, it is rec-
ommended that all studies report concomitant analge-
sics and doses since without these data it is difficult to
assess the true magnitude of effect of o-3 PUFA supple-
mentation. In addition, we recommend use of high-dose
o-3 PUFAs (at least 2.7 elday of EPA and DHA) for a
minimum duration of 3 months using a non-olive oil
placebo control condition.
Are EPA/DHA supplements useful for other types of
chronic inflammatory pain? Many patients with osteoar-
thritis or chronic back pain might benefit from alterna-
tives to NSAIDs, yet there are no controlled clinical
trials at present. Inflammation was found to be more
prominent in the early stages of osteoarthritis compared
to the latter stages (Benito et a1.,2005), suggesting the
early stages might be more susceptible to EPA/DHA.
Consistent with the prostaglandin dependent mecha-
nism underlying dysmenorrhea, pain associated with
the menstrual cycle was reduced by fish oil combined
with vitamin Bl2 (Deutch et al., 2000) and by Neptune
krill oil, which is enriched in rrr-3 PUFAs (Sampalis
et al., 2003).
The mechanisms by which ro-3 PUFAs reduce pain are
not known. It remains to be determined empirically
whether the ability of EPA/DHA to reduce pain is due
to one or more of the following possibilities: suppression
of the inflammation underlying RA or inflammatory
bowel disease; direct effects on prostaglandins or possibly
cytokines in the spinal cord dorsal horn. Evidence is
equivocal for an EPA/DHA mediated reduction in cyto-
kine secretion in humans. As reviewed by Calder (2006),
some studies that supply high-dose EPA or DHA to
healthy volunteers (e.g., Kelley et al., 1999) resulted in
a suppression of TNF-u or IL-lB release by monocytes,
whereas a number of other studies (e.g., Kew eta1.,2004)
failed to detect any changes in cytokine release.
Chronic neuropathic pain consequent to physical or
viral injury to sensory nerves is mediated in part by
hyperexcitable dorsal horn neurons (Marchand et al.,
2005; Takeda et a1.,2005; Wieseler-Frank et a1., 2005),
but it is a less attractive target for EPA/DHA than is
chronic inflammatory pain. There are important differ-
ences in the mechanisms to these two types of chronic
pain. Animal models of chronic neuropathic pain
induced by spinal root ligation or sciatic nerve constric-
tion show that prostaglandins are required to initiate the
process, but are not nec€ssary for its maintenance; and
NSAIDs have limited efficacy in chronic neuropathic
pain (Broom et a1.,2004; Takeda et al., 2005). Rather,
a critical factor in neuropathic pain is the activation in
the spinal cord of non-neural glial cells, microglia and
astrocytes (Marchand el al., 2005; Wieseler-Frank
et a1.,2005). Activated glia are characterized by prolifer-
ation, hypertrophy, and increased production of proin-
flammatory cytokines, such as IL-10, TNF-u, and
interleukin-6 (IL-6). Inhibitors of IL-lB administered
intrathecally can reduce neuropathic pain, while trans-
genic mice with absent IL-l signalling fail to develop
neuropathic pain (Sweitzer et al., 20011' Marchand
et al., 2005; Honore et al., 2006; Wolf et al., 2006). Glial
activation was observed in one rat study of inflammato-
ry pain induced by complete-Freund's adjuvant, but not
in other reports (Zhang et a1.,2003; Raghavendra et al.,
2004; Honore et al., 2006). In chronic neuropathic pain
animal models, microglia also secrete brain-derived neu-
rotrophic factor (BDNF). This inverts the polarity of
currents activated by the neurotransmitter y-amino
butyric acid, thereby causing disinhibition of dorsal
horn neurons (Coull et al., 2005). Of these mechanisms
of neuropathic pain, the production of inflammatory
cytokines might potentially be reduced by EPA/DHA,
but as noted above this is unclear. One study examined
the effect of feeding various plant oils to rats following
partial sciatic nerve ligation (Perez et al., 2005). In that
report, heat hyperalgesia correlated negatively with the
amount of o-linolenic acid in the test diets, raising the
possibility that rrl-3 PUFAs may enhance neuropathic
pain. Since a-linolenic acid is poorly converted to EPA
and DHA (James et a1., 2003), further experiments are
needed to directly test the effects of EPA and DHA in
a neuropathic pain model.
In summary, the results of the present meta-analysis,
examining or-3 PUFA supplementation in patients with
rheumatoid arthritis or joint pain secondary to inflam-
matory bowel disease and dysmenorrhea, suggest that
EPA/DHA supplementation reduces patient assessed
joint pain intensity, morning stiffness, number of painful
and/or tender joints, and NSAID consumption. Omega-
3 PUFA supplementation is an attractive adjunctive
treatment for joint pain. Further studies in humans are
required to optimize the analgesic effects of EPA/DHA
in patients with arthritis and other types of chronic
inflammatory pain.
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